Application of aspartate aminotransferase to cholinesterase ratio for predicting hepatic fibrosis in patients with chronic hepatitis B

Dan HUANG,Wei LU,Jie WANG,Zheng-hua ZHANG,Yun-he PAN,Zhan-qing ZHANG

DOI: https://doi.org/10.16118/j.1008-0392.2018.01.015

2018-01-01

Abstract:Objective To evaluate the application of aspartate aminotransferase to cholinesterase ratio (ACR) versus aspartate aminotransferase to platelet ratio(APR) in predicting the severity of hepatic fibrosis in patients with chronic hepatitis B (CHB).Methods Total 1 335 HBeAg positive and 1 026 HBeAg negative patients with CHB were enrolled.According to Scheuer score system,pathological stage ≥ S2 was defined as significant hepatic fibrosis,and ≥ 4 was defined as cirrhosis.The ROC curve was used to assess the value of ACR and APR in predicting the hepatic fibrosis and cirrhosis.Results In HBeAg positive patients,the areas under the ROC curves (AUC) of ACR and APR for predicting significant hepatic fibrosis were 0.772 and 0.765 respectively,and those for predicting cirrhosis were 0.751 and 0.756,respectively;with ACR＞0.200 and APR＞ 1.000 as cutoff values,the sensitivity,specificity of ACR and APR for predicting significant hepatic fibrosis were 60.4％,79.2％ and 56.8％,78.8％,respectively,and those for predicting cirrhosis were 77.3％,61.2％ and 76.2％,63.8％,respectively.In HBeAg negative patients,the AUC of ACR and APR for predicting significant hepatic fibrosis were 0.756 and 0.741 respectively,and those for predicting cirrhosis were 0.805 and 0.786 respectively;with ACR＞0.125 and APR＞0.750 as cutoff values,the sensitivity,specificity of ACR and APR for predicting significant hepatic fibrosis were 59.0％,80.4％ and 58.1％,79.8％,respectively,and those for predicting cirrhosis were 80.7％,68.3％ and 80.2％,68.5％,respectively.Conclusion The cutoff values of ACR and APR for predicting significant hepatic fibrosis and cirrhosis in HBeAg positive patients are inconsistent with those in HBeAg negative patients;the sensitivity and specificity of ACR for predicting significant hepatic fibrosis and cirrhosis are consistent with those of APR regardless of HBeAg positive or negative patients.